SG11201403980VA - Anesthetic compounds and related methods of use - Google Patents

Anesthetic compounds and related methods of use

Info

Publication number
SG11201403980VA
SG11201403980VA SG11201403980VA SG11201403980VA SG11201403980VA SG 11201403980V A SG11201403980V A SG 11201403980VA SG 11201403980V A SG11201403980V A SG 11201403980VA SG 11201403980V A SG11201403980V A SG 11201403980VA SG 11201403980V A SG11201403980V A SG 11201403980VA
Authority
SG
Singapore
Prior art keywords
related methods
anesthetic compounds
anesthetic
compounds
methods
Prior art date
Application number
SG11201403980VA
Other languages
English (en)
Inventor
Douglas E Raines
Syed Shaukat Husain
John C R Randle
Original Assignee
Gen Hospital Corp
Annovation Biopharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Annovation Biopharma Llc filed Critical Gen Hospital Corp
Publication of SG11201403980VA publication Critical patent/SG11201403980VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
SG11201403980VA 2012-01-13 2013-01-11 Anesthetic compounds and related methods of use SG11201403980VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261586450P 2012-01-13 2012-01-13
US201261622627P 2012-04-11 2012-04-11
PCT/US2013/021245 WO2013106717A1 (en) 2012-01-13 2013-01-11 Anesthetic compounds and related methods of use

Publications (1)

Publication Number Publication Date
SG11201403980VA true SG11201403980VA (en) 2014-08-28

Family

ID=48781947

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201403980VA SG11201403980VA (en) 2012-01-13 2013-01-11 Anesthetic compounds and related methods of use

Country Status (24)

Country Link
US (4) US9156825B2 (enExample)
EP (2) EP3184512B1 (enExample)
JP (1) JP6196986B2 (enExample)
CN (2) CN104168899B (enExample)
AU (1) AU2013207811B2 (enExample)
BR (1) BR112014017230A2 (enExample)
CA (1) CA2861071C (enExample)
CY (1) CY1118842T1 (enExample)
DK (1) DK2802325T3 (enExample)
EA (1) EA027976B1 (enExample)
ES (1) ES2617536T3 (enExample)
HR (1) HRP20170330T1 (enExample)
HU (1) HUE030892T2 (enExample)
IN (1) IN2014DN06132A (enExample)
LT (1) LT2802325T (enExample)
NZ (1) NZ627274A (enExample)
PL (1) PL2802325T3 (enExample)
PT (1) PT2802325T (enExample)
RS (1) RS56025B1 (enExample)
SG (1) SG11201403980VA (enExample)
SI (1) SI2802325T1 (enExample)
SM (1) SMT201700145T1 (enExample)
WO (1) WO2013106717A1 (enExample)
ZA (1) ZA201405248B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3360863T3 (da) * 2015-10-10 2022-06-13 Jiangsu Nhwaluokang Pharmceutical Res And Development Co Ltd Etomidatderivat og mellemprodukt, fremgangsmåde til fremstilling og anvendelse deraf
CN105663042A (zh) * 2016-02-03 2016-06-15 北京蓝丹医药科技有限公司 一种稳定的麻醉药物脂肪乳及其制备方法
CN107382870A (zh) * 2016-05-17 2017-11-24 四川海思科制药有限公司 N‑取代咪唑羧酸酯类化合物及其制备方法和在医药上的用途
CN107445898A (zh) * 2016-05-30 2017-12-08 四川海思科制药有限公司 N‑取代咪唑羧酸酯类化合物及其制备方法和在医药上的用途
CN107522662A (zh) * 2016-06-16 2017-12-29 四川海思科制药有限公司 N‑取代咪唑羧酸酯类化合物及其制备方法和在医药上的用途
CN107641105A (zh) * 2016-07-22 2018-01-30 四川海思科制药有限公司 N‑取代咪唑羧酸酯类化合物及其制备方法和在医药上的用途
CN106432163A (zh) * 2016-09-29 2017-02-22 山东东方农药科技实业有限公司 一种螺环内酯类化合物、其合成方法以及其用途
CN107652239B (zh) * 2017-02-24 2020-08-04 四川大学华西医院 N-取代咪唑羧酸酯类化合物、制备方法及用途
CN116120295A (zh) * 2018-01-30 2023-05-16 成都麻沸散医药科技有限公司 一种n-取代咪唑甲酸酯类衍生物及其用途
CN109053410A (zh) * 2018-08-06 2018-12-21 兰博尔开封科技有限公司 一种合成1-羟基环己基甲酸的新工艺及应用
WO2020063676A1 (zh) 2018-09-26 2020-04-02 江苏恒瑞医药股份有限公司 依喜替康类似物的配体-药物偶联物及其制备方法和应用
US12377163B2 (en) 2018-09-30 2025-08-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd Anti-B7H3 antibody-exatecan analog conjugate and medicinal use thereof
CN109761906B (zh) * 2019-03-02 2023-08-11 成都麻沸散医药科技有限公司 一种取代咪唑甲酸酯类衍生物及其用途
CN110003188B (zh) * 2019-03-27 2022-08-26 成都麻沸散医药科技有限公司 取代吡咯甲酸酯类衍生物及其用途
BR112022004913A2 (pt) 2019-09-18 2022-06-07 Baili Bio Chengdu Pharmaceutical Co Ltd Derivado de camptotecina e conjugado do mesmo
CN112174890B (zh) * 2020-10-09 2022-05-27 成都麻沸散医药科技有限公司 酮取代杂环化合物及其麻醉作用
EP4043440A4 (en) * 2019-10-11 2023-11-08 Chengdu Mfs Pharma. Co., Ltd. SUBSTITUTED NITROGEN HETEROCYCLE COMPOUND AND ANESTHESIZING EFFECT THEREOF
CN110669017B (zh) * 2019-10-11 2023-08-04 成都麻沸散医药科技有限公司 多取代三唑甲酸酯类衍生物及其用途
KR20220113728A (ko) 2019-12-12 2022-08-16 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항 클라우딘 항체 약물 접합체 및 그 의약 용도
BR112022011632A2 (pt) 2019-12-16 2022-10-04 Jiangsu Hengrui Medicine Co Conjugado análogo de anticorpo exatecano anti-cea e uso farmacêutico do mesmo
WO2021148003A1 (zh) 2020-01-22 2021-07-29 上海森辉医药有限公司 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用
US20230101735A1 (en) 2020-01-22 2023-03-30 Jiangsu Hengrui Medicine Co., Ltd. Anti-trop-2 antidody-exatecan analog conjugate and medical use thereof
MX2022011769A (es) 2020-03-25 2022-10-18 Jiangsu Hengrui Pharmaceuticals Co Ltd Metodo de preparacion de medicamento de conjugado de anticuerpo.
JP2023519261A (ja) 2020-03-25 2023-05-10 江蘇恒瑞医薬股▲ふん▼有限公司 抗psma抗体-エキサテカン類似体複合体及びその医薬用途
EP4129345A4 (en) 2020-03-25 2023-11-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. PHARMACEUTICAL COMPOSITION COMPRISING AN ANTIBODY-DRUG CONJUGATE AND USE THEREOF
CN117460540A (zh) 2021-07-22 2024-01-26 上海森辉医药有限公司 艾日布林衍生物的药物偶联物
JP2025500952A (ja) 2021-12-23 2025-01-15 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 抗dll3抗体、その抗体-薬物複合体及びその医薬的使用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3354173A (en) 1964-04-16 1967-11-21 Janssen Pharmaceutica Nv Imidazole carboxylates
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CA1066709A (en) 1975-03-10 1979-11-20 Walter A.M. Helsen Preparation of loweralkyl imidazole carboxylates
US4038286A (en) 1975-03-10 1977-07-26 Janssen Pharmaceutica N.V. Racemates and optical isomers of 1-(1-phenylethyl)-1h-imidazole-5-carboylic acid derivatives
GR64915B (en) 1978-09-14 1980-06-09 Janssen Pharmaceutica Nv Improved etomidate-containing compositions
EP0277384A3 (en) 1986-12-24 1990-05-23 Janssen Pharmaceutica N.V. 1h-imidazole-5-carboxylic acid derivatives
US4878940A (en) 1987-04-02 1989-11-07 Janssen Pharmaceutica N.V. Herbicidal 1,5-substituted 1H-imidazoles
AU629290B2 (en) 1989-01-31 1992-10-01 Merrell Dow Pharmaceuticals Inc. Novel aryl-or heteroaryl-1-alkyl-pyrrole-2-carboxylic acid compounds useful in treating interleukin-1 mediated conditions
US5041554A (en) 1989-01-31 1991-08-20 Merrell Dow Pharmaceuticals Inc. Novel aryl-or heteroaryl-1-alkyl-pyrrole-2-carboxylic acid compounds useful in treating interleukin-1 mediated conditions
US5019583A (en) 1989-02-15 1991-05-28 Glaxo Inc. N-phenyl-N-(4-piperidinyl)amides useful as analgesics
US5242939A (en) 1990-09-28 1993-09-07 Warner-Lambert Company Anilide derivatives with angiotensin ii antagonist properties
JP3374922B2 (ja) 1991-05-09 2003-02-10 日産化学工業株式会社 複素環式第3級アミンの製造方法
JPH06345728A (ja) 1993-06-11 1994-12-20 Nissan Chem Ind Ltd N−置換アゾール誘導体の製造方法
US5466700A (en) 1993-08-30 1995-11-14 Glaxo Wellcome Inc. Anesthetic use of N-phenyl-N-(4-piperidinyl)amides
US5756528A (en) 1995-06-06 1998-05-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5997898A (en) 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
WO2002074200A1 (en) 2001-03-20 2002-09-26 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
WO2003057219A1 (en) 2001-12-27 2003-07-17 Ortho-Mcneil Pharmaceutical Inc. Aroyl pyrrole heteroeryl and methanols useful for treating a central nervous system disorder
US7189859B2 (en) 2003-08-06 2007-03-13 Ilse Zolle Radiolabelled phenylethyl imidazole carboxylic acid ester derivatives
US20080206138A1 (en) 2003-08-06 2008-08-28 Ilse Zolle Radiolabelled Phenylethyl Imidazole Carboxylic Acid Ester Derivatives
JP2008510726A (ja) 2004-08-20 2008-04-10 エントレメッド インコーポレイテッド プロテイナーゼ活性化受容体アンタゴニストを含む組成物および方法
US7592362B2 (en) * 2006-01-19 2009-09-22 Pfizer Limited Substituted imidazoles
CN101374518B (zh) 2006-01-24 2012-02-08 日本脏器制药株式会社 新型组氨酸衍生物
EP2035393A2 (en) 2006-06-09 2009-03-18 GE Healthcare Limited Synthesis and evaluation of 18f-labelled alkyl-1-[(r)-1-phenylethyl]-1h-imidazole-5-carboxylate as a tracer for the quantification of beta-11-hydroxylase enzyme in the adrenal glands
CN101743227B (zh) 2007-07-23 2013-09-25 日本脏器制药株式会社 组氨酸衍生物
WO2009146024A1 (en) * 2008-03-31 2009-12-03 The General Hospital Corporation Etomidate analogues with improved pharmacokinetic and pharmacodynamic properties
CA2767112C (en) 2009-07-10 2018-06-19 The General Hospital Corporation Etomidate analogues that do not inhibit adrenocortical steroid synthesis

Also Published As

Publication number Publication date
US9820971B2 (en) 2017-11-21
SI2802325T1 (sl) 2017-04-26
DK2802325T3 (en) 2017-03-13
US20150328189A1 (en) 2015-11-19
ZA201405248B (en) 2017-04-26
PL2802325T3 (pl) 2017-11-30
JP6196986B2 (ja) 2017-09-13
CN107382812A (zh) 2017-11-24
AU2013207811A1 (en) 2014-07-31
EP3184512A1 (en) 2017-06-28
LT2802325T (lt) 2017-03-10
US9156825B2 (en) 2015-10-13
US10154991B2 (en) 2018-12-18
CA2861071C (en) 2017-09-12
SMT201700145T1 (it) 2017-05-08
NZ627274A (en) 2015-10-30
WO2013106717A1 (en) 2013-07-18
HRP20170330T1 (hr) 2017-04-21
CA2861071A1 (en) 2013-07-18
RS56025B1 (sr) 2017-09-29
BR112014017230A2 (pt) 2020-11-24
AU2013207811B2 (en) 2017-08-10
CN104168899B (zh) 2017-04-05
EA201491362A1 (ru) 2014-12-30
PT2802325T (pt) 2017-03-01
US9522136B2 (en) 2016-12-20
CN104168899A (zh) 2014-11-26
ES2617536T3 (es) 2017-06-19
IN2014DN06132A (enExample) 2015-08-14
EP2802325B1 (en) 2016-11-30
EP3184512B1 (en) 2020-12-23
JP2015508415A (ja) 2015-03-19
EA027976B1 (ru) 2017-09-29
HUE030892T2 (hu) 2017-07-28
US20180098968A1 (en) 2018-04-12
US20150203476A1 (en) 2015-07-23
US20170273951A1 (en) 2017-09-28
EP2802325A1 (en) 2014-11-19
EP2802325A4 (en) 2015-06-10
CY1118842T1 (el) 2018-01-10

Similar Documents

Publication Publication Date Title
ZA201405248B (en) Anesthetic compounds and related methods of use
IL276761B1 (en) Methods of inducing coma
SG10201609940RA (en) Compounds and their methods of use
ZA201502503B (en) Hppd variants and methods of use
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
SG11201502343RA (en) Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
ZA201308859B (en) Quinazolines as therapeutic compounds and related methods of use
SI2717898T1 (sl) Spojine prokoagulantov in metode za njihovo uporabo
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
EP2879676A4 (en) SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE
ZA201406082B (en) Use of ccr3-inhibitors
EP2709999A4 (en) QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
ZA201408856B (en) Heteroaryl compounds and methods of use thereof
ZA201408128B (en) Etract of greyia radlkoferi and use thereof
GB201216381D0 (en) New compounds and medical uses
GB201208970D0 (en) New compounds and medical uses